

Additional file 4: Analysis by dose for particular statins

Atorvastatin

Total cholesterol

Trials with			Patients on atorvastatin			Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration	Baseline	Absolute	Percent
5	5	All combined	1334	1334	12/52 wks	7.2	-2.0	-27
4	4	10	1107	1107	12/52 wks	7.2	-2.0	-27
1	1	10/20	227	227	52 wks	7.2	-2.0	-28

LDL

Trials with			Patients on atorvastatin			Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed	Duration	Baseline	Absolute	Percent
5	5	All combined	1334	1334	12/52 wks	5.0	-1.8	-36
4	4	10	1107	1107	12/52 wks	5.0	-1.8	-37
1	1	10/20	227	227	52 wks	5.0	-1.8	-35

HDL

Trials with			Patients on atorvastatin			Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed	Duration	Baseline	Absolute	Percent
5	5	All combined	1334	1334	12/52 wks	1.3	0.1	7
4	4	10	1107	1107	12/52 wks	1.3	0.1	7
1	1	10/20	227	227	52 wks	1.3	0.1	7

Triglycerides

Trials with			Patients on atorvastatin			Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed	Duration	Baseline	Absolute	Percent
5	5	All combined	1334	1334	12/52 wks	2.0	-0.3	-17
4	4	10	1107	1107	12/52 wks	2.0	-0.3	-17
1	1	10/20	227	227	52 wks	1.9	-0.3	-17

Note: Randomised: Number of patients randomised in trials which provided baseline cholesterol or triglycerides

Cerivastatin

Total cholesterol

Trials with		Patients on cerivastatin				Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration	Baseline	Absolute	Percent
4	4	All combined	2316	2316	12-52	7.4	-1.6	-22
1	1	0.025	193	193	12	7.7	-0.7	-9
1	1	0.05	187	187	12	7.6	-0.9	-12
1	1	0.1	190	190	12	7.6	-1.3	-18
2	2	0.2	353	353	12-24	7.3	-1.5	-21
0	0	0.3	no data	no data				
2	2	0.4	527	527	24-52	7.0	-1.7	-25
1	1	0.8	776	776	52	7.1	-2.1	-29
1	1	0.05-0.3	260	260	32	8.1	-1.3	-16

LDL

Trials with		Patients on cerivastatin				Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration	Baseline	Absolute	Percent
5	5	All combined	2828	2828	12-52	5.2	-1.4	-26
1	1	0.025	193	193	12	5.6	-0.7	-12
1	1	0.05	187	187	12	5.6	-0.9	-16
2	2	0.1	356	356	12/16	5.4	-1.1	-20
3	3	0.2	524	524	12-24	5.1	-1.4	-28
1	1	0.3	175	175	16	5.2	-1.3	-24
2	2	0.4	527	527	24-52	4.8	-1.7	-36
1	1	0.8	776	776	52	5.0	-1.6	-33
1	1	0.05-0.3	260	260	32	6.0	-1.4	-23

HDL

Trials with		Patients on cerivastatin				Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration	Baseline	Absolute	Percent
4	4	All combined	2316	2316	12-52	1.3	0.1	7
1	1	0.025	193	193	12	1.3	0.003	0.2
1	1	0.05	187	187	12	1.4	0.02	1
1	1	0.1	190	190	12	1.3	0.1	4
2	2	0.2	353	353	12-24	1.4	0.04	5
1	1	0.3	no data					
2	2	0.4	527	527	24-52	1.3	0.1	8
1	1	0.8	776	776	52	1.2	0.1	10
1	1	0.05-0.3	260	260	32	1.2	0.1	9

triglycerides

Trials with		Patients on cerivastatin				Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration	Baseline	Absolute	Percent
5	5	All combined	2998	2998	12-52	2.1	-0.3	-13
1	1	0.025	193	193	12	1.6	-0.03	-0.2
1	1	0.05	187	187	12	1.5	-0.1	-6
2	2	0.1	356	190	12/16	2.3	-0.3	-13
3	3	0.2	524	524	12-24	2.1	-0.2	-11
1	1	0.3	175	175	16	3.1	-0.4	-12
2	2	0.4	527	527	24-52	1.9	-0.2	-12
1	1	0.8	776	776	52	2.1	-0.4	-18
1	1	0.05-0.3	260	260	32	2.0	-0.2	-9

Note: Randomised: Number of patients randomised in trials which provided baseline cholesterol or triglycerides

Fluvastatin

Total cholesterol

Trials with			Patients on fluvastatin			Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration (wks)	Baseline	Absolute	Percent
9	9	All combined	1209	1209	12-52	7.5	-1.6	-21
5	5	40	376	376	12-24	7.6	-1.3	-17
1	1	80	175	175	24	7.3	-1.8	-24
1	1	10-20	237	237	18	6.0	-1.8	-27
1	1	20-40	100	100	18	8.4	-1.8	-22
2	2	40-80	321	321	16/52	7.5	-1.4	-19

LDL

Trials with			Patients on fluvastatin			Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration (wks)	Baseline	Absolute	Percent
9	8	All combined	1209	1022	12-52	5.3	-1.6	-30
5	5	40	376	376	12-24	5.4	-1.3	-24
1	1	80	175	175	24	5.2	-1.8	-34
1	1	10-20	237	237	18	4.7	-1.7	-36
1	1	20-40	100	100	18	6.4	-1.8	-28
2	2	40-80	321	134	16/52	5.6	-1.7	-30

HDL

Trials with			Patients on fluvastatin			Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration (wks)	Baseline	Absolute	Percent
9	8	All combined	1209	1022	12-52	1.3	0.1	7
5	5	40	376	376	12-24	1.3	0.1	6
1	1	80	175	175	24	1.3	0.1	8
1	1	10-20	237	237	18	1.2	0.1	10
1	1	20-40	100	100	18	1.3	0.1	4
2	2	40-80	321	134	16/52	1.4	0.1	8

Triglycerides

Trials with			Patients on fluvastatin			Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration (wks)	Baseline	Absolute	Percent
9	8	All combined	1209	1022	12-52	1.9	-0.2	-10
4	4	40	376	376	12-24	2.0	-0.1	-6
1	1	80	175	175	24	1.9	-0.3	-14
1	1	10-20	237	237	18	2.0	-0.2	-11
1	1	20-40	100	100	18	1.5	-0.2	-11
2	2	40-80	321	134	16/52	2.0	-0.3	-15

Note: Randomised: Number of patients randomised in trials which provided baseline cholesterol or triglycerides

Lovastatin

Total cholesterol

Trials with			Patients on lovastatin			Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration (wks)	Baseline	Absolute	Percent
13	13	All combined	8561	8394	12 wks - 2 yrs	6.9	-1.2	-17
3	3	20	1967	1967	16-48 wks	6.7	-1.2	-17
4	4	40	3743	3743	12-48 wks	6.8	-1.5	-23
3	3	80	1870	1870	14 wks - 2 yrs	6.8	-2.0	-29
1	1	10-60	24	24	18 wks	7.8	-2.5	-32
4	3	20-40	149	96	12-18 wks	7.3	-1.5	-21
3	3	20-80	653	653	18 wks - 2 yrs	7.3	-1.2	-17
2	2	40-80	156	156	12 wks	10.0	-3.2	-32

LDL

Trials with			Patients on lovastatin			Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration (wks)	Baseline	Absolute	Percent
13	13	All combined	8561	8561	12 wks - 2 yrs	4.8	-1.5	-30
3	3	20	1967	1967	16-48 wks	4.7	-1.1	-24
4	4	40	3743	3743	12-48 wks	4.8	-1.4	-30
3	3	80	1870	1870	14 wks - 2 yrs	4.8	-1.6	-34
1	1	10-60	24	24	18 wks	5.8	-2.6	-45
4	4	20-40	149	149	12-18 wks	5.3	-1.6	-31
3	3	20-80	653	653	18 wks - 2 yrs	5.2	-1.9	-36
2	2	40-80	156	156	12 wks	7.5	-3.0	-40

HDL

Trials with			Patients on lovastatin			Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration (wks)	Baseline	Absolute	Percent
13	13	All combined	8561	8561	12 wks - 2 yrs	1.2	0.1	7
3	3	20	1967	1967	16-48 wks	1.2	0.1	6
4	4	40	3743	3743	12-48 wks	1.2	0.1	8
3	3	80	1870	1870	14 wks - 2 yrs	1.2	0.1	9
1	1	10-60	24	24	18 wks	1.3	0.2	15
4	4	20-40	149	149	12-18 wks	1.2	0.1	9
3	3	20-80	653	653	18 wks - 2 yrs	1.2	-0.1	-8
2	2	40-80	156	156	12 wks	1.2	0.1	8

Triglycerides

Trials with			Patients on lovastatin			Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration (wks)	Baseline	Absolute	Percent
13	13	All combined	8561	8561	12 wks - 2 yrs	1.8	-0.3	-15
3	3	20	1967	1967	16-48 wks	1.8	-0.2	-11
4	4	40	3743	3743	12-48 wks	1.8	-0.3	-15
3	3	80	1870	1870	14 wks - 2 yrs	1.7	-0.3	-19
1	1	10-60	24	24	18 wks	1.8	-0.5	-25
3	3	20-40	105	105	12-18 wks	1.9	-0.3	-14
3	3	20-80	653	653	18 wks - 2 yrs	1.9	-0.3	-17
2	2	40-80	156	156	12 wks	1.9	-0.3	-15

Note: Randomised: Number of patients randomised in trials which provided baseline cholesterol or triglycerides

Pravastatin

Total cholesterol

Trials with			Patients on pravastatin			Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration (wks)	Baseline	Absolute	Percent
44	42	All combined	11811	9730	12 wks - 5 yrs	6.6	-1.3	-20
4	4	10	258	258	12-24 wks	7.1	-1.3	-18
1	1	15	48	48	52 wks	7.3	-1.6	-25
9	9	20	889	889	12-52 wks	7.2	-1.5	-20
17	16	40	8716	6635	12 wks - 5 yrs	6.5	-1.3	-21
2	2	10-20	154	154	26/52 wks	6.6	-0.9	-14
6	6	10-40	705	705	16-24 wks	7.6	-1.3	-18
6	6	20-40	972	972	12 wks - 3 yrs	7.0	-1.3	-19
1	1	40-80	68	68	16 wks	8.0	-1.7	-21

LDL

Trials with			Patients on pravastatin			Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration (wks)	Baseline	Absolute	Percent
44	44	All combined	11811	11811	12 wks - 5 yrs	4.5	-1.2	-27
4	4	10	258	258	12-24 wks	5.0	-1.0	-19
1	1	15	48	48	52 wks	5.3	-1.6	-30
9	9	20	889	889	12-52 wks	5.0	-1.4	-27
17	17	40	8716	8716	12 wks - 5 yrs	4.4	-1.2	-28
2	2	10-20	154	154	26/52 wks	4.6	-1.0	-22
6	6	10-40	705	705	16-24 wks	5.6	-1.3	-25
6	6	20-40	972	972	12 wks - 3 yrs	4.9	-1.3	-26
1	1	40-80	68	68	16 wks	5.6	-1.7	-30

HDL

Trials with			Patients on pravastatin			Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration (wks)	Baseline	Absolute	Percent
44	43	All combined	11811	9730	12 wks - 5 yrs	1.1	0.1	12
4	4	10	258	258	12-24 wks	1.3	0.1	7
1	1	15	48	48	52 wks	1.2	0.1	9
9	9	20	889	889	12-52 wks	1.2	0.1	6
18	17	40	9730	7649	12 wks - 5 yrs	1.1	0.2	14
2	2	10-20	154	154	26/52 wks	1.2	0.1	9
6	6	10-40	705	705	16-24 wks	1.3	0.2	17
6	6	20-40	972	972	12 wks - 3 yrs	1.2	0.1	8
1	1	40-80	68	68	16 wks	1.4	0.1	9

Triglycerides

Trials with			Patients on pravastatin			Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration (wks)	Baseline	Absolute	Percent
44	42	All combined	11811	9730	12 wks - 5 yrs	1.8	-0.2	-12
4	4	10	258	258	12-24 wks	1.5	0.0	-7
1	1	15	48	48	52 wks	1.7	-0.2	-11
9	9	20	889	889	12-52 wks	1.9	-0.2	-12
18	17	40	9730	7649	12 wks - 5 yrs	1.8	-0.2	-12
2	2	10-20	154	154	26/52 wks	1.9	-0.1	-4
6	6	10-40	705	705	16-24 wks	1.6	-0.3	-22
6	6	20-40	972	972	12 wks - 3 yrs	1.8	-0.2	-14
1	1	40-80	68	68	16 wks	1.5	-0.2	-15

Note: Randomised: Number of patients randomised in trials which provided baseline cholesterol or triglycerides

Rosuvastatin

Total cholesterol

Trials with		Patients on rosuvastatin				Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration (wks)	Baseline	Absolute	Percent
4	4	All combined	1005	1005	12	7.2	-2.2	-31
4	4	5	510	510	12	7.3	-2.2	-30
4	4	10	495	495	12	7.0	-2.3	-33

LDL

Trials with		Patients on rosuvastatin				Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration (wks)	Baseline	Absolute	Percent
4	4	All combined	1005	1005	12	4.8	-2.2	-46
4	4	5	510	510	12	4.8	-2.1	-44
4	4	10	495	495	12	4.8	-2.3	-49

HDL

Trials with		Patients on rosuvastatin				Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration (wks)	Baseline	Absolute	Percent
4	4	All combined	1005	1005	12	1.0	0.1	9
4	4	5	510	510	12	1.0	0.1	8
4	4	10	495	495	12	1.0	0.1	9

Triglycerides

Trials with		Patients on rosuvastatin				Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration (wks)	Baseline	Absolute	Percent
4	4	All combined	1005	1005	12	2.0	-0.4	-18
4	4	5	510	510	12	2.0	-0.3	-16
4	4	10	495	495	12	2.5	-0.4	-19

Note: Randomised: Number of patients randomised in trials which provided baseline cholesterol or triglycerides

Simvastatin

Total cholesterol

Trials with			Patients on simvastatin			Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration (wks)	Baseline	Absolute	Percent
31	31	All combined	17168	17168	12 wks - 5 yrs	6.1	-1.6	-25
1	1	2.5	60	60	12 wks	7.1	-0.9	-13
1	1	5	60	60	12 wks	7.3	-1.3	-18
2	2	10	126	126	24/52 wks	5.7	-1.6	-29
11	11	20	1313	1313	12 wks - 4 yrs	6.5	-1.4	-21
4	4	40	10952	10952	24 wks - 3.5 yrs	5.7	-1.5	-26
1	1	80	669	669	24 wks	7.9	-2.8	-35
2	2	5-10	211	211	12 wks	6.9	-0.7	-11
1	1	5-40	127	127	32 wks	7.9	-1.8	-23
4	4	10-20	392	392	12/52 wks	7.4	-1.3	-18
7	7	10-40	852	852	18 wks - 2 yrs	7.3	-1.6	-22
3	3	20-40	2406	2406	16 wks - 5 yrs	6.5	-1.6	-25

LDL

Trials with			Patients on simvastatin			Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration (wks)	Baseline	Absolute	Percent
31	31	All combined	17168	17168	12 wks - 5 yrs	4.0	-1.4	-34
1	1	2.5	60	60	12 wks	4.9	-0.9	-18
1	1	5	60	60	12 wks	5.2	-1.3	-26
2	2	10	126	126	24/52 wks	5.2	-1.0	-19
11	11	20	1313	1313	12 wks - 4 yrs	4.8	-1.8	-37
4	4	40	10952	10952	24 wks - 3.5 yrs	3.4	-1.2	-34
1	1	80	669	669	24 wks	5.8	-2.7	-47
2	2	5-10	211	211	12 wks	4.9	-1.1	-22
1	1	5-40	127	127	32 wks	5.7	-1.8	-32
4	4	10-20	392	392	12/52 wks	5.4	-1.6	-30
7	7	10-40	852	852	18 wks - 2 yrs	5.2	-1.6	-30
3	3	20-40	2406	2406	16 wks - 5 yrs	4.9	-1.7	-35

HDL

Trials with			Patients on simvastatin			Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration (wks)	Baseline	Absolute	Percent
31	30	All combined	17168	16938	12 wks - 5 yrs	1.1	0.1	6
1	1	2.5	60	60	12 wks	1.3	0.1	8
1	1	5	60	60	12 wks	1.4	0.1	4
2	2	10	126	126	24/52 wks	1.3	0.1	5
11	11	20	1313	1313	12 wks - 4 yrs	1.2	0.1	8
4	4	40	10952	10952	24 wks - 3.5 yrs	1.1	0.0	4
1	1	80	669	669	24 wks	1.3	0.1	8
2	2	5-10	211	211	12 wks	1.3	0.1	10
1	1	5-40	127	127	32 wks	1.3	0.1	11
4	4	10-20	392	392	12/52 wks	1.1	0.1	12
7	7	10-40	852	852	18 wks - 2 yrs	1.2	0.2	11
3	3	20-40	2406	2406	16 wks - 5 yrs	1.2	0.1	8

Triglycerides

Trials with			Patients on simvastatin			Weighted mean change		
Baseline data	Outcome data	Daily dose (mg)	Randomised	Analysed for outcome data	Duration (wks)	Baseline	Absolute	Percent
30	30	All combined	17039	17039	12 wks - 5 yrs	2.0	-0.4	-17
1	1	2.5	60	60	12 wks	1.9	-0.1	-5
1	1	5	60	60	12 wks	1.7	-0.1	-3
2	2	10	126	126	24/52 wks	1.5	-0.2	-12
11	11	20	1313	1313	12 wks - 4 yrs	1.9	-0.3	-17
4	4	40	10952	10952	24 wks - 3.5 yrs	2.2	-0.4	-18
1	1	80	669	669	24 wks	1.8	-0.4	-24
2	2	5-10	211	211	12 wks	1.7	-0.1	-9
1	1	5-40	127	127	32 wks	1.2	-0.1	-10
4	4	10-20	392	392	12/52 wks	1.9	-0.3	-14
7	7	10-40	852	852	18 wks - 2 yrs	1.8	-0.4	-22
2	2	20-40	2277	2277	16 wks - 5 yrs	1.5	-0.2	-10

Note: Randomised: Number of patients randomised in trials which provided baseline cholesterol or triglycerides